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Osteoclast activities are responsible for the resorption of bone cells found in several bone diseases, one of which is 
periodontitis and arthritis. The upregulating signals of Receptor Activator of Nuclear Factor kB (RANK)-RANK Ligand and 
Tumor Necrosis Factor  (TNF)-a are the major cause of the bone destruction. Studies and experiments have been performed 
to overcome this matter. Various medications are now available to treat bone-related diseases, targeting the specific aspect 
of the signaling. Synthetic drugs such as denosumab and bisphosphonates have complex pharmacological action and have 
been the leading choice in treatment. Evidence in studies proved that natural resources including herbal products have 
potential application to therapy for bone loss, with caffeic acid and Caffeic Acid Phenethyl Ester (CAPE) showing significant 
inhibitory results and Chinese herbs such as Herba epimedii (Yín Yáng Huò) and Fructus psoraleae (Bǔ Gǔ Zhī) proved to 
contain components that give similar effects to estrogen. The purpose of this review is to discuss the therapy value of 
available synthetic and natural therapeutic agents. Understanding the mechanisms of both agents will not only clarify their 
function as therapeutic agents, but can also be the key to the treatment of diseases caused by bone resorption by targeting 
specific aspects of osteoclastogenesis.
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Introduction
The bone loss progression seen in periodontitis is a result 
of excessive cytokine production, one of which is Receptor 
Activator of Nuclear Factor kB (RANK) Ligand (RANKL). 
RANK and RANKL signaling plays a prominent role in 
osteoclastogenesis, producing osteoclast cells. The binding 
of RANK-RANKL signaling induces Tumor Necrosis 
Factor (TNF) Receptor Associated Factor (TRAF) 6 
and further leads to activation of its cascades such as 
Extracellular Signal-Regulated Kinase (ERK), Janus 
N-terminal Kinase (JNK), Nuclear Factor kB (NFkB), and 
p38 Mitogen-activated Protein Kinase (MAPK).1 The p38 
MAPK has important roles in cell’s homeostasis such as 
cell proliferation, differentiation, maturation, apoptosis, and 
cytokine production, which makes p38 MAPK one of the 
key factors in osteoimmunology.2 Therefore a therapeutic 
agent is needed to subdue this problem, and there is now 
evidence showing that not only synthetic medications but 
natural products can influence by inhibiting bone resorption 
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process. Vegetables including onion, garlic, and parsley 
were reported to inhibit bone resorption in ovariectomized 
rats, while herbs like thyme, rosemary, and sage, increase 
bone mineral density.3 Caffeic acid is a natural resource 
that has many uses as a therapeutic agent, one of which is 
to inhibit N-Nitrosation in vitro to inhibit the formation of 
mutagens and carcinogens. A study in 2011 showed that 
caffeic acid successfully suppresses osteoclastogenesis 
significantly by suppressing the activity NFkB.4 Another 
natural source is Stewartia koreana was reported to suppress 
osteoclast differentiation successfully.5 Drugs developed 
from synthetic substances including Bisphosphonates, 
Denosumab, Methotrexate (MTX) and Risedronate were 
also reported to have positive effects as a therapeutic agent 
of bone resorption related diseases.6,7 This review aims to 
introduce therapeutic options available for bone resorption 
diseases. Understanding the options and mechanisms will 
not only clarify their function as therapeutic agents but can 
also be the key to the treatment of diseases caused by bone 
resorption.
Periodontitis
Periodontitis defined by the American Academy of 
Periodontology as inflammation of the teeth supporting 
tissues that are usually characterized by progressive 
destructive changes that cause bone and periodontal 
ligament loss and an inflammatory response of the gingiva 
to the bone and ligaments adjacent.8 This disease is an 
opportunistic infection caused by plaque. Plaque is a mass 
that mostly composed of microorganisms that stick to the 
teeth, prosthesis, and the surface of the mouth. The roles of 
plaque containing these microorganisms have been analyzed 
many years and are now introduced to the concept called 
osteoimmunology, which means researchers are focusing 
their study on the signaling system between the immune 
system and bone cells.- In periodontal diseases, anaerobic 
bacteria and spirochetes grow in subgingival tissue then 
multiply into colonies and invade the host, generating 
irritation reactions and signs of inflammation. Extracts of 
Aggregatibacter actinomycetemcomitans has bacterial 
lipopolysaccharide (LPS) that induces a potent chemokine 
called interleukin (IL)-8. Induction of this chemokine 
will lead dendritic cells, neutrophils, macrophages, and 
lymphocytes to infiltrate the tissues and initiate the immune 
system. Stimulation of the bacteria then produces an 
inflammatory response in the form of excessive cytokine 
formation, which will initiate and exacerbate periodontal 
diseases.1
     The initial stage of infection begins with the activation 
of a mechanical shield that acts as a non-specific immune 
defense system leading to initial inflammatory response. 
B and T lymphocytes soon are activated when the 
bacteria begins to invade the tissues. A study states that 
the researchers are considering the T lymphocytes as an 
important bone regulator not only in periodontitis but also in 
other cases. T lymphocytes activate macrophages, indirectly 
activating the expression of osteoclast precursors and 
RANKL. Current knowledge shows that RANK/RANKL/
Osteoprotegerin (OPG) signaling is involved in bone 
resorption process in patients suffering from periodontal 
disease. RANKL promotes bone resorption, while OPG 
inhibits bone resorption. Several studies were carried out 
to examine the levels of RANKL and OPG in patients with 
periodontitis. It was reported that patients with patients 
with periodontitis had lower levels of OPG.10 However, a 
study in ameloblastoma cell line showed that in a situation 
where OPG, TRAIL, and low level of RANKL  present, 
OPG preferably binds to TRAIL, suppressing it’s ability to 
induce apoptosis in ameloblastoma. TRAIL has the highest 
apoptotic ability compared to TNF-a and RANKL, making 
the existence of OPG should be considered.10 In addition to 
RANKL, TNF-a also plays an important role in inducing 
inflammation that exacerbates periodontitis.11 Based on the 
data above, it is clear that pro-inflammatory mediators are the 
main cause of the increased severity of periodontal diseases 
and many of these cytokines are obtained from activated 
p38 MAPK whose activities depend on phosphorylation of 
tyrosine and threonine.1
Osteoclastogenesis
Bone is a dynamic organ where it is constantly changing 
to reach its normal function called the bone remodeling 
process. Old bone cells will be degraded by the osteoclasts 
and replaced with new ones by osteoblasts. Therefore, the 
balance between bone formation and resorption process 
is vital to maintain bone’s normal state.12 Osteoclast is a 
multinucleated cell whose function is to resorp bone, derived 
from hematopoietic stem cells, and is made of myeloid 
progenitor cells involving fused mononuclear cells.4,13 
Osteoclast precursors undergo a series of differentiation 
stages  resulting  mature  cells  capable  of  destroying  the 
bone. 
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     Hematopoietic stem cells are divided into two major 
groups, common myeloid progenitor (CMP) and the 
common lymphoid progenitor (CLP). Osteoclast comes 
from CMP, a bifurcation from monocyte/macrophage 
lineage while CLP induces lymphoid lineage cells such 
as T lymphocytes, B lymphocytes and other natural killer 
cells.15 A study showed that osteoblastic cells are also 
required for osteoclast differentiation. Osteoblastic cells 
produce Macrophague Colony Stimulating Factor (M-CSF), 
even though M-CSF alone is not sufficient to induce 
osteoclastogenesis. M-CSF enhances the proliferation and 
survival of osteoclast precursors and helps the survival of 
mature osteoclast cells.14
RANK-RANKL Signaling
The binding of RANK and RANKL is one of the major 
factors that affect osteoclastogenesis, proved in a study on 
mice. Osteopetrosis was seen in mice that had a shortage 
in RANK and RANKL induction.15 RANKL is a member 
of the TNF superfamily, which is a protein found on the 
surface of mesenchymal osteoblast lineage, binding to 
its receptor, RANK, which will activate the osteoclast 
phenotype. Production of RANKL can be increased by 
parathyroid hormones that act as a stimulant agent of 
the osteoclast.16 RANK does not have intrinsic enzyme 
activity in its intracellular domain; it converts the energy to 
recruit adapter molecules such as proteins TRAF family to 
overcome this. TRAF is a cytoplasmic adapter protein that 
binds to the intracellular domain of various receptor of TNF 
receptor (TNFR).17  
     Among all TRAFs, TRAF 6 is the most important 
adapter for RANK-RANKL to induce osteoclastogenesis.18 
The relationship between TRAF6 and RANK will form a 
complex signaling, Transforming Growth Factor (TGF)-
β-activated kinase (TAK) 1 and TAK1-binding protein 2 
which induce 3 MAPK signaling pathways such as ERK, 
p38 MAPK and JNK (Figure 1). The induction of TRAF6 
in the RANK signaling is crucial in the phosphorylation 
process of RANK-induced NFkB.19 TRAF 6 will continue 
the signals to NFkB, ERK, p38 MAPK, JNK, Akt, c-Fos, 
c-Src and Microphthalmia-inducing Transcription Factor 
(MITF).20,21 RANKL induces Nuclear Factor of Activated 
T cells (NFATc)1 complex by inducing the expression of 
the c-Fos family and supporting c-Jun signaling.22 NFATc1 
regulates several osteoclast-specific genes, including the 
tartrate-resistant acid phosphatase, osteoclast-associated 
receptor and cathepsin K.22  The important roles of NFATc1 
in osteoclastogenesis have been studied with in vitro 
and in vivo tests carried out on mice. In in vitro studies, 
human embryonic stem cells that lack NFATc1 failed to 
differentiate into osteoclast, and in vivo observations, the 
Figure 1. RANK-RANKL osteoclastogenesis signaling pathway. PIP2: phosphatidylinositol (4,5)-bisphosphate; PIP3: 
phosphatidylinositol (3,4,5)-trisphosphate; TAB: TAK1-binding protein; PDK: phosphoinositide-dependent protein kinase; IκB: Inhibitor 
of κB; IKK: IκB kinase.
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absence of  NFATc1  in  young  mice  would  result  in 
osteopetrosis proving that NFATc1 plays an important role 
on osteoclastogenesis.23 
 RANKL also activates Phosphoinositides 3-kinase 
(PI3K)/Akt through TRAF6, PI3K/Akt has a close 
relationship with Src kinase activity.24  The absence of cellular 
Src kinase will inhibit phosphorylation of RANKL-induced 
Akt. Activated PI3K then creates phosphatidylinositol-
(3,4,5)-phosphate in the plasma membrane, which then 
recruits Akt. PI3K inhibitor LY294002 was reported to 
inhibit osteoclast formation. The data above shows that the 
signaling of PI3K is involved in the differentiation process 
of the osteoclast.25  
TNF Signaling
While RANK-RANKL signaling is a major signaling in 
osteoclastogenesis, proinflammatory cytokines together with 
RANK and RANKL play an important role in osteoclast’s 
differentiation and activation.26 TNF-a also induces 
osteoclast formation in vitro by activating the NFkB and 
JNK. In fact, in vitro studies have hypothesized that TNF-a 
may induce osteoclastogenesis even when RANK-RANKL 
signaling is not present. TNF-a is formed by macrophages, 
monocytes and lymphocytes T. A study in mice showed 
an increased formation of osteoclast precursors in mice 
that had higher concentrations of TNF-a. TNF-a is part 
of TNF superfamily and plays an important role in various 
cell activities such as cell proliferation, differentiation, 
maintenance and apoptosis.27 TNF-a induces paired Ig-like 
receptor-A (PIR-A), which is a co-stimulatory receptor for 
RANK to stimulate osteoclastogenesis.28
     TNF-a also induces osteoclast precursor and marrow 
stromal cells that will express TNF receptor type 1 and 
produce proinflammatory cytokines, such as IL-1, RANKL 
and M-CSF. M-CSF then binds to c-fms, a tyrosine 
kinase receptor that induces osteoclast differentiation by 
activating ERK1/2 and PI3K/Akt giving direct impact on 
osteoclastogenesis.29 Great recognition has been given 
towards TNF-a as numerous studies about anti-TNF 
treatment showed promising results in reducing bone 
erosions and inflammation.30,31
M-CSF
Osteoblasts or the cells derived from new bones express 2 
main cytokines contributing to osteoclast differentiation, 
RANKL and M-CSF. Osteoclast precursors express M-CSF’s 
receptor called c-Fms and RANK, which is RANKL’s 
receptor. Their bindings play a major role in osteoclast 
differentiation.32 M-CSF is a molecule that plays a big role 
in precursor’s survival and proliferation. A study confirmed 
that op/op mice that failed to express functioning M-CSF 
are osteopetrosis. Another study mentioned mice lacking 
csf1r or the gene coding for c-Fms, experience a decrease 
in tissue macrophages and severe osteopetrosis confirming 
the evidence above.33 The binding of M-CSF and c-fms has 
a complex downstream signals, however, to simplify it, 
M-CSF induces signaling in primary macrophages such as 
PI3K, p42/44 ERK, and c-Cbl. These are key transducers of 
M-CSF signaling.34 
Available Bone Resorption Inhibitor 
The normal function of bone metabolism is deeply 
influenced by the balance of bone mineralization and 
resorption. However, the balance needed in maintaining 
bone’s health is often compromised due to aging and bone 
related diseases. Thus, researchers have been studying 
prospecting materials to be developed as a potential therapy 
for bone related diseases.
Synthetic Resources as Bone Resorption 
Inhibitor
Resorption inhibitor drugs have been the most common 
therapy when it comes to dealing with bone related diseases. 
Drugs can influence osteoclast’s activity in many ways 
with their own biochemical mechanisms, many of which 
are created to help reduce bone resorption thus helping 
the healing process of the bone. Treatments have been 
varied from hormones such as estrogens and calcitonin to 
Denosumab which is an anti-RANKL antibody.35 
Bisphosphonates
Bisphosphonates are potent bone resorption inhibitors and 
have been used as primary and therapeutic agents for bone 
related diseases such as osteogenesis imperfecta, heritable 
skeletal disorder in children, postmenopausal, glucocorticoid-
induced osteoporosis, and bone metastases in malignancy 
cases. Bisphosphonates inhibit bone’s calcification and 
hydroxyapatite breakdown making it an effective bone 
resorption inhibitor. Newer generations of bisphosphonates 
such as alendronate, risedronate, ibandronate,  pamidronate, 
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and zoledronic acid have nitrogen in their chains by which 
promote osteoclast apoptosis more efficiently compared to 
non-nitrogen bisphosphonates.36  Further study  showed  that 
alendronate and  pamidronate inhibited osteoclastogenesis 
but did not target RANKL and OPG expression.37 They 
inhibit farnesyl diphosphate synthase which is a cholesterol 
biosynthesis pathway enzyme,  and  by  suppressing 
geranylgeranylation, osteoclast function is lost, and bone 
resorption progress is inhibited.38  However, prolonged 
consumption  of  bisphosphonates  may increase the 
potential  for  diseases such as osteonecrosis of the jaw, 
atypical fractures, and esophageal cancer.39
Trichostatin A
Trichostatin A is one of histone deacetylases inhibitor, 
which is an enzyme involved in the transcriptional activity 
and the remodeling of chromatin’s structure. A study was 
conducted to analyze the effects of TSA on RANKL induced 
osteoclast formation and results showed a significant 
decrease of c-Fos and NFATc1 which play a big role in early 
osteoclastogenesis.40 Further evidence showed TSA leads 
mature osteoclasts into apoptotic cell death thus making it 
a suitable candidate as a bone related therapeutic agent.41 
Lastly, TSA was reported to successfully inhibit osteoclast 
formation in co-culture of bone marrow cells and osteoblasts 
without reducing RANKL expression in osteoblasts. It was 
further explained that TSA suppressed RANKL-induced 
osteoclast formation from primary bone marrow-derived 
macrophages and only effective when present during the 
early stage of osteoclast differentiation.42 
Methotrexate
Methotrexate is a folic acid inhibitor that binds to 
dihydrofolate reductase thus inhibiting the synthesis 
of deoxyribonucleic acid (DNA) and ribonucleic acid 
(RNA).43  Methotrexate  is  currently  one  of  the  most 
common therapies for rheumatoid arthritis patients. 
Rheumatoid arthritis is often characterized by synovial 
membrane inflammation  and  bone  destruction,  which 
can  be measured  by  the  increment  of  RANKL/OPG 
ratio. A  study  showed that Methotrexate decreased 
RANKL/OPG ratio and blocked  M-CSF-RANKL induced 
osteoclastogenesis which makes Methotrexate a direct 
osteoclastogenesis inhibitor. Methotrexate is effective and 
safe, however, mucositis and oral ulceration can occur as 
side effects of the treatment, depending on the dosage. It 
has also been reported that folate deficiency plays a role 
in predisposing mucositis induced by methotrexate. Due 
to this, supplementation with folinic acid has been proven 
effective to help fight the side effects of methotrexate 
without compromising its therapeutic action.44
Denosumab
Denosumab is a human monoclonal antibody that inhibits 
bone resorption by mimicking the effects of OPG thus 
inhibiting the binding of RANKL and RANK, a major 
signaling in osteoclastogenesis. Denosumab works by 
targeting RANKL specifically, making it unlikely to affect 
other regulatory systems.7 A study was conducted to 
evaluate Denosumab’s efficacy and safety, it was reported 
that Denosumab effectively increases the bone mass density 
(BMD) in postmenopausal women that had been treated 
with Denosumab for 2 years.45 While Denosumab has been 
shown to be a safe therapy choice, there is a possible side 
effect that might need further correlation study called frozen 
bone process. Complete inhibition of bone remodeling 
process leads to increment of microfractures thus increasing 
the risk of atypical femoral fracture called the frozen bone 
process.7
Natural Resources as Bone Resorption 
Inhibitor
Evidence in studies proved that natural sources including 
herbal products could participate in these processes thus 
giving beneficial factors to bone’s well-being. A group 
of vegetables consists of onion, garlic and parsley was 
reported to have the ability to inhibit bone resorption in 
ovariectomized rats. Essential oils are taken from thyme, 
sage, rosemary and other herbs inhibit osteoclast activity 
thus increasing bone mineral density. Soya bean, usually 
known for its rich source of isoflavones has shown promising 
results to use as a therapeutic agent in maintaining bone 
health.3 
     On a more specific level, caffeic acid (3,4-dihydroxy-
cinnamic acids) is a molecule found on a variety of plants, 
one of which is yam that has an inhibitory effect towards 
osteoclastogenesis by inhibiting NFkB.4,46 It’s derivative, 
caffeic acid phenethyl ester (CAPE) has been shown 
to have anti-inflammatory component and suppresses 
osteoclastogenesis. CAPE significantly inhibited osteoclast 
formation induced by RANKL and proposed as a therapeutic 
agent for bone related diseases.47
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Onion 
Onion (Allium cepa) is a species member of Allium genus 
and  is  a widely used  food  ingredient.  Its  beneficial 
properties have been studied, and evidence showed that 
onion inhibited bone resorption in rats in a dose dependant 
manner.48 Onion powder solution was reported to inhibit 
osteoclastogenesis by inhibiting RANKL-induced ERK, 
p38 MAPK, and NFkB activation but did not affect the 
differentiation and maturation of cultured osteoblasts. 
Current studies’ data suggest that onion enriched diet might 
be beneficial to bone’s health and prevent bone loss related 
diseases.49
Caffeic acid
Caffeic  acid  is  one  of  hydroxycinnamic  acids  found 
in green  plants and food sources such as berries, potatoes, 
coffee, carrots  and  sweet  potato  that  has  been  studied 
by scientists to evaluate its beneficial properties.4,50  Caffeic 
acid is a  natural  resource  that  has  many  uses  as  a 
therapeutic agent, one of which is to inhibit N-Nitrosation 
in vitro, which can prevent the formation of mutagenic 
and carcinogenic compounds. A study in 2011 showed 
caffeic acid’s significant inhibitory ability towards 
osteoclastogenesis  by suppressing NFkB activity. A detailed 
mechanism of how caffeic acid inhibits osteoclastogenesis 
remains unclear.4 However, a further study explained that 
caffeic acid did not significantly affect the expression of 
TRAF 6 while significantly suppressed NFkB’s activity 
in TRAF 6-transfected RANKL-TNF-a-induced RAW-D 
cells.51 Apoptotic induction by caffeic acid has also been 
reported in cancer cells such as SCM1 Gastric, HeLa 
cervical cancer cells, and lastly, MG-63 osteosarcoma cell 
line, through a series of caspase activation.52 
CAPE 
     CAPE is an active compound found in the extract of 
propolis collected by bees from several plant species. CAPE 
fights viruses, works as an anti-inflammatory, anti-mitogenic, 
anti-carcinogenic, and an effective immunomodulator.53 It 
has been shown that CAPE has a positive impact on wound 
healing and inhibits osteoclastic activity, which benefits new 
bone formation. CAPE does not have a significant influence 
on the phosphorylation of p38 MAPK, JNK and ERK in 
the bone marrow cells of mice and fights bone resorption 
by suppressing RANKL-induced NFkB/NFATc activity and 
inducing osteoclast apoptosis.54,55
Soy isoflavones
     Flavanoids have been reported to enhance bone formation 
and inhibit bone resorption through various signaling 
pathways that influence the bone metabolism. Flavanoids 
can be found in fruits, vegetables, herbs, spices, essential 
oils, and beverages. Soy isoflavones is a member of the 
flavanoid family that has been studied for their role in bone 
health and can be found in soya beans.56 Soy isoflavones 
called as daidzain and genistein often found in soybeans have 
a similar structure to estrogen and have the ability to bind to 
the estrogen receptor. A study showed that isoflavones might 
help postmenopausal women to prevent osteoporosis.57,58 In 
addition, soy isoflavones suppress osteoclastic activities by 
working like estrogens, inhibiting c-Fos-induced NFATc1 
expression.59
Other natural resources
Traditional herbal medicine has been widely used amongst 
the Chinese and Ayurvedic medical practice.3 Turmeric 
root (Curcuma longa) for example, a staple ingredient in 
Chinese and Ayurvedic medical practice has an active 
ingredient called curcumin that has been proven to prevent 
osteoclastogenesis while also has anti-inflammatory and 
antioxidant characteristics.60 Chinese traditional herbs such 
as Herba epimedii (Yín Yáng Huò) and Fructus psoraleae 
(Bǔ Gǔ Zhī) contain components that give similar effects to 
estrogen that may have the potential to be developed as new 
phytoestrogens.61 Other Chinese traditional herbs called 
Malva verticillata showed promising results suppressing 
osteoclast activities by inhibiting c-Fos, NFATc1, the 
phosphorylation of c-Jun N-terminal kinase, p38, inhibitor 
of kBα (IkB)α and phospholipase γ2.62 Stewartia koreana, 
a natural plant product found in Korea also reported 
having a strong inhibitory effect on osteoclast formation 
by suppressing the induction of c-Fos and NFATc1 by 
RANKL.5 
Conclusion
Bone resorption process is a complex mechanism that 
involves various bone metabolism pathways creating 
mature osteoclast cells. Understanding the mechanisms 
of bone resorption is one of the keys to treat bone-related 
diseases. Various treatments have been discovered from 
synthetic drugs to natural resources. While synthetic drugs 
are more commonly known for its benefits, it comes with a 
package of potential side effects. On the other hand, natural 
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resources might have the potential to treat bone-related 
diseases without the harming side effects of synthetic drugs, 
targeting specific aspects of the osteoclastogenesis pathways 
to provide suiting therapy for bone related diseases.
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